|Bid||1.17 x 1000|
|Ask||1.23 x 900|
|Day's Range||1.1300 - 1.6000|
|52 Week Range||0.2700 - 3.3000|
|Beta (3Y Monthly)||-0.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.00|
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Every investor in Pernix Therapeutics Holdings, Inc.Read More...
NEW YORK, NY / ACCESSWIRE / February 14, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Pernix Therapeutics Holdings, Inc., (PTX) Pernix is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market. During the third quarter, Contrave remained the leading prescription weight loss brand in the United States, and the company is currently exploring a number of initiatives to enhance the value of the brand globally. Pernix is extremely encouraged with the initial results from Contrave, which is the market-leading branded weight loss prescription drug.
John Sedor became the CEO of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) in 2016. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After Read More...
The Morristown, New Jersey-based company said it had a loss of 89 cents per share. The pharmaceutical posted revenue of $37.2 million in the period. In the final minutes of trading on Thursday, the company's ...
If you’re interested in Pernix Therapeutics Holdings Inc (NASDAQ:PTX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock Read More...
John Sedor took the helm as Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX) CEO and grew market cap to US$28.02M recently. Understanding how CEOs are incentivised to run and grow their companyRead More...
If you are looking to invest in Pernix Therapeutics Holdings Inc’s (NASDAQ:PTX), or currently own the stock, then you need to understand its beta in order to understand how itRead More...
Stock Monitor: Pernix Therapeutics Holdings Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Amarin Corp. PLC (NASDAQ: ...